WHO ICTRP trial
A Single-Center, Randomized, Double-Blind, Placebo-Controlled…
ChiCTR2500106384 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500106384 |
|---|---|
| Public title | A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Administration and Multiple-Administration Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of IMBZ18g in Healthy Chinese Subjects |
| Scientific title | Evaluation of a single center, randomized, double-blind, placebo-controlled, single dose, and multiple dose escalation phase I clinical study of IMBZ18g in Chinese healthy subjects |
| Primary sponsor | The Third Hospital of Changsha |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | healthy subjects |
| Interventions | SAD stage IMBZ18g group:Six dose groups (100mg,250mg,500mg,1000mg,2000mg and 3000mg) will perform intravenous infusion of administration on an empty stomach.;SAD stage placebo group:Five dose groups (250mg,500mg,1000mg,2000mg and 3000mg)… |
| Registration date | Jul 23, 2025 |
| Target size | SAD stage IMBZ18g group:32;SAD stage placebo group:10;MAD stage IMBZ18g… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: